Disco Pharmaceuticals GmbH announced the final close of its seed round at €36 million (US$42 million), as it shapes up novel ...

Experience gained in the Asia-Pacific region is helping shape the Menarini Group’s global strategy as the Italian ...

Absci Corp. has released new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor (PRLR) ...

Researchers from Wuhan Institute of Biomedical Sciences, Jianghan University and collaborators recently showed that ...

Two new therapies are now FDA approved to treat the sexually transmitted infection gonorrhea, with Innoviva Inc.’s Nuzolvence ...

Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab ...

Rezolute Inc.’s phase III Sunrize study of its only candidate, ersodetug, a fully human monoclonal antibody that binds to ...

Formation Bio Inc. acquired ex-China rights to Lynk Pharmaceuticals Co. Ltd.’s oral TYK2-inhibitor, LNK-01006, for up to $605 ...

The cardiomyositis that is a rare adverse effect of mRNA-based COVID vaccines is due to immune cell activity as a result of ...

AC Immune SA plans talks with regulators based on positive interim safety and efficacy results from the phase II Vacsyn trial ...

Many cases of human immunodeficiency virus (HIV)-1 infection can be effectively treated with existing drugs, but they can ...

Restricting the recommended use of COVID-19 vaccines in the U.S. wasn’t enough. Now the Children’s Health Defense (CHD) is ...